Shares of Kala Pharmaceuticals, Inc. (KALA) are rising more than 6% Friday morning at $16.43.
The company today said Combangio, Inc., a unit of Kala, has been awarded a $15 million grant by the California Institute for Regenerative Medicine (CIRM) to support the company’s ongoing study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED).
KALA has traded in the range of $3.54-$56.72 in the last 1 year.
Source: Read Full Article
Lates News:
-
Crypto Markets Muted Ahead Of An Eventful Week
-
Driving Bitcoin's Surge: MicroStrategy Founder on Education, Adoption, and Policy Impact
-
Bitcoin ($BTC) Price to Rise to $30,000 in Second Half of 2023, VanEck Says
-
Analyst PlanB On How Current BTC HODLers Will Lay the Foundation for The Next Bitcoin Bull Run
-
Cryptos Climb Despite A Firm Dollar And Lingering Fed Fears